Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | TOP1 | P11387 | 6/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5570863 | 1.00 | KCNH2 (0.48) | KCNH2SCN5ATOP1PIM1CDK2 | |
| SCHEMBL5278078 | 1.00 | KCNH2 (0.48) | KCNH2SCN5ATOP1PIM1CDK2 | |
| Hydrochloric Acid SCHEMBL7507134 | 0.99 | KCNH2 (0.47) | KCNH2SCN5ATOP1PIM1CDK2 | |
| SCHEMBL8567585 | 0.95 | KCNH2 (0.43) | KCNH2SCN5ATOP1PIM1CDK2 | |
| SCHEMBL8600110 | 0.94 | KCNH2 (0.42) | KCNH2SCN5ATOP1PIM1CDK2 | |
| Hydrochloric Acid SCHEMBL7494375 | 0.94 | KCNH2 (0.42) | KCNH2SCN5ATOP1PIM1CDK2 | |
| Hydrochloric Acid SCHEMBL7545787 | 0.94 | KCNH2 (0.41) | KCNH2SCN5ATOP1PIM1CDK2 | |
| SCHEMBL8575780 | 0.93 | KCNH2 (0.40) | KCNH2SCN5ATOP1PIM1CDK2 | |
| Hydrochloric Acid SCHEMBL9062772 | 0.93 | SCN5A (0.42) | KCNH2SCN5ATOP1 | |
| Hydrochloric Acid SCHEMBL8561939 | 0.93 | KCNH2 (0.40) | KCNH2SCN5ATOP1PIM1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101065385-A | Rifamycin derivatives for treating microbial infections | CUMBRE PHARMACEUTICALS INC (US) | 2007-10-31 | — | — | CN | disclosed |
| US-7229996-B2 | Rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060019985-A1 | Rifamycin derivatives | CUMBRE INC. (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019985-A1 | Rifamycin derivatives | RIF1, NQO1, MRM1 | KCNH2 2117/4885SCN5A 2077/4885TOP1 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.